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Abstract
Proteomics based biological research is greatly expanded by high quality mass spectrometry 
studies, which are themselves enabled by access to quality mass spectrometry resources, such as 
high-quality curated proteome data repositories. We present a PeptideAtlas for the domestic 
chicken, containing an extensive and robust collection of chicken tissue and plasma samples with 
substantial value for the chicken proteomics community for protein validation and design of 
downstream targeted proteome quantitation. The Chicken PeptideAtlas contains 6,646 canonical 
proteins at a protein FDR of 1.3%, derived from ~100,000 peptides at a peptide level FDR of 
0.1%. The rich collection of readily accessible data is easily mined for the purposes of data 
validation and experimental planning, particularly in the realm of developing proteome 
quantitation workflows. Herein we demonstrate the use of the atlas to mine information on 
common chicken acute phase proteins and biomarkers for cancer detection research, as well as 
their localization and polymorphisms. This wealth of information will support future proteome-
based research using this highly important agricultural organism in pursuit of both chicken and 
human health outcomes.
Graphical Abstract
Keywords
Biomarkers; Chicken; Ovarian Cancer; PeptideAtlas
Corresponding Author: David C. Muddiman, Ph.D., W.M. Keck FT Mass Spectrometry Laboratory, Department of Chemistry, North 
Carolina State University, Raleigh, North Carolina 27695, Phone: 919-513-0084, david_muddiman@ncsu.edu. 
Links to the GUI front-end of the chicken PeptideAtlas are available for reviewers at: https://db.systemsbiology.net/sbeams/cgi/
PeptideAtlas/main.cgi?SBEAMSentrycode=G71UmfA
The related SRMAtlas, containing a reference library of SRM transitions derived in these experiments, will be available in 2017.
Author Contributions
All authors have given approval to the final version of the manuscript.
HHS Public Access
Author manuscript
J Proteome Res. Author manuscript; available in PMC 2018 March 30.
Published in final edited form as:
J Proteome Res. 2017 March 03; 16(3): 1352–1363. doi:10.1021/acs.jproteome.6b00952.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
INTRODUCTION
The domestic laying hen (Gallus gallus) is the most abundant avian species on the planet1 
and a cornerstone species in food production and classical embryological study.2 This 
importance was underscored by its selection as the first classical “production” organism to 
be fully genome sequenced, in 2004.3 With the establishment of functional genomic tools 
for the chicken, it has officially entered the post-genomic era dominated by proteomic 
studies.4
Mass spectrometry (MS) based proteomics has reached widespread acceptance as a powerful 
tool to study organisms and protein products through multiple stages of disease, 
development, and degradation.5 While the experimental techniques are well developed and 
robust, the application of proteomic methods to non-classical model organisms remains 
nascent. This is particularly true for organisms of predominantly agricultural interest, such 
as chickens, whose investigators frequently lack access to advanced MS resources available 
to human health researchers.6 The result is that only ~10% of the chicken genome is well 
annotated7,8 in spite of the enormous potential power of the chicken as a biological model 
system and its substantive importance as an agricultural product. The chicken was a classic 
model organism for embryological development in the pre-genomic era and the development 
of genetic tools have returned it to the fore.2,9 Further, the hen ovary exhibits many similar 
genetic and physiological traits to humans and is the only non-human animal known to 
spontaneously develop ovarian cancer.10,11
Clearly there is enormous medical and economic potential in proteomics studies involving 
Gallus gallus that is limited by access to MS resources and the incomplete nature of chicken 
proteomic/genomic databases. Successful mass spectrometry experiments are greatly 
enabled by access to publicly available databases of validated data, such as those found in 
PeptideAtlas12 or the ProteomeXchange13 consortium database, PRIDE;14,15 however, these 
databases are currently devoid of substantial information regarding the domestic hen. The 
completion of a reference database for chicken proteomics would substantially advance 
experimental planning and data validation for global and targeted analysis in this model 
system.
PeptideAtlas (http://www.peptideatlas.org) curates and compiles mass spectrometry data 
derived from a variety of experiments through the reprocessing of available MS data using 
the Trans-Proteomic Pipeline (TPP), a freely available open source suite of tools for tandem 
MS experiments.16–18 The resulting proteome builds contain high stringency (<1.5% false 
discovery rate (FDR)) protein-level identifications and peptide observations from numerous 
experiments in a readily accessible interface, one that is particularly well suited to the 
evaluation of candidate peptides for targeted proteomics via SRM or data-independent 
approaches such as DIA.19 More recently, the TPP has also incorporated the iterative 
reSpect algorithm to assess spectral chimeras and identify peptides that would otherwise be 
missed.20 PeptideAtlas contains numerous well studied proteomes and model organisms 
such as Saccharomyces cerevisiae with > 70% proteome coverage,21 and includes classical 
agriculturally important organisms, such as the pig (Sus scrofa domesticus)22 and the co 
(Bos Taurus)23.
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Here we present an initial build of a chicken PeptideAtlas, containing a variety of 
structurally complex ovarian tissue types, as well as diagnostically relevant plasma samples. 
Currently, the chicken PeptideAtlas is directed toward the hen as an ovarian cancer model 
organism, but data from liver tissue and plasma are included as a useful baseline, and 
additional tissue types will be incorporated into later builds. We demonstrate the current 
utility of the atlas through the mining of reported ovarian cancer biomarkers, as well as 
general inflammatory response proteins, and the selection of candidate peptides for 
quantitative SRM analysis.
EXPERIMENTAL PROCEDURES
Sample Collection and Processing
The biological samples included in the chicken PeptideAtlas were collected from two 
cohorts of Bovan’s white leghorn commercial laying hens in the Poultry Science department 
at North Carolina State University. Birds were managed in accordance with the Institute for 
Laboratory Animal Research Guide with all of the husbandry practices being approved by 
and under the oversight of North Carolina State University Institutional Animal Care and 
Use Committee (IACUC). Plasma and tissue from the initial cohort of B-strain hens were 
obtained in a previous study,24 with samples collected from a second cohort of 300 C-strain 
hens similarly. In brief, ~2mL of blood was collected from each bird every four months 
beginning at an age of 26 weeks. The collected blood was centrifuged at 3000 × g at 4 °C 
and the plasma was collected in cryogenic tubes for long term storage at −80 °C. At an age 
of 136 weeks the birds were sacrificed by cervical dislocation and dissected to ascertain 
gross internal pathology. Tissue was collected from all birds presenting neoplastic lesions on 
the ovary, oviduct, duodenum, pancreas, GI tract, and/or liver as well as from a selected 
number of “healthy” birds with no visible distress. Tissues were preserved for proteomic 
study by snap freezing in liquid nitrogen and stored at −80 °C.
Whole tissue samples were lysed using a 1:5 ratio of tissue to buffer containing 50 mM Tris 
pH = 7.8, 8 M urea, 2 M thiourea, 10 mM EDTA, 10 mM DTT, and 0.001 % sodium azide 
and homogenized using an OMNI TIP Homogenizing kit, as described previously.25 A 
subset of liver and ovary tissues were instead subjected to laser microdissection to isolate 
yolk, ovarian stroma, and follicular wall tissue, which were subsequently lysed in a buffer of 
100 mM Tris-HCl, pH 7.5, 100 mM dithiothreitol (DTT), and 4% sodium dodecyl sulfate.26 
Plasma samples were used as collected.
Cell lysates and plasma were processed for LC-MS/MS analyses using either a 1D SDS-
PAGE in-gel digestion protocol24,25 or filter aided sample preparation (FASP)27 as described 
previously26. A subset of the FASP prepared samples were de-glycosylated on-filter using 
peptide-N-glycosidase F (PNGase F) according to a combined glycomics and proteomics 
protocol28.
LC-MS/MS Analyses
Peptide samples were analyzed by LC-MS/MS using one of three sets of conditions:
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1. Separation was performed on a nanoLC-2D (Eksigent Technologies) coupled to 
an LTQ-FT-Ultra with a 7T FT-ICR Mass Analyzer (Thermo Scientific) in a 
vented column configuration29. The column consisted of a 75 μm × 5 cm 
Integrafrit trap and 75 μm × 15cm Picofrit column (New Objective) self-packed 
with 5μm Magic C18AQ stationary phase. Mobile phases A and B consisted of 
98/2/0.2 and 2/98/0.2 water/ACN/formic acid, and the separation was performed 
as a 60 minute gradient from 2–60% B at a flow rate of 350 nL/min. Data was 
collected in Top-8 data-dependent mode over a mass range of 400 – 1600 m/z 
with a full scan resolving power of 100,000 FWHM @ 400 m/z using IT-CID 
and an AGC target of 1e6. Dynamic exclusion windows of 3 minutes were 
applied to each MS/MS precursor mass.
2. Separation was conducted with an EASY nLC II (Thermo Scientific) was 
coupled to a Q Exactive benchtop mass spectrometer (Thermo Scientific). The 
trap and column were arranged in the vented column configuration as in (1), and 
used a mobile phase gradient of 2%–5% B (2 min), 5%–40% B (200 min) at a 
flow rate of 300 nL/min. Parameters for the mass spectrometer were set 
according to optimums derived for proteomics experiments on the Q Exactive.30 
Briefly, data was collected in Top-12 data-dependent MS/MS mode using HCD 
with a full scan mass range of 400 – 1600 m/z, a full scan resolving power of 
70,000 and MS/MS resolving power of 17,500 FWHM @ 200 m/z, and a 
dynamic exclusion window of 30 s. AGC targets were set at 1e6 and 2e5 for full 
scan and MS/MS scan respectively, with complementary maximum injections 
times of 30ms and 250ms.
3. Chromatographic separation was carried out with an EASY nLC-1000 (Thermo 
Scientific) coupled to a Q Exactive HF (Thermo Scientific). A 75 μm × 5cm trap 
was prepared with a frit synthesized as described by Meiring et al.31 and coupled 
to a 75 μm × 30 cm Picofrit emitter (New Objective). Both were self-packed with 
2.6 mm, 100 Å particle size C18 stationary phase (Phenomenex) and assembled 
in the same column setup as in (1) and (2). Peptides were separated by a gradient 
of 2 – 20% B (100 min), 20 – 32% B (30 min) at 300 nL/min. MS parameters 
were independently optimized for proteomics experiments on the Q Exactive HF 
and are reported in Hecht et al.28 The data was collected in Top 20 data-
dependent MS/MS mode using HCD with a 15 s dynamic exclusion window, a 
full scan mass range of 375–1500 m/z and resolving power of 120,000 and 
15,000 FWHM @ 200 m/z for the MS1 and MS2 scans respectively. The full 
scan AGC and injection were set to 1e6 and 30ms for the MS1 scan and 1e5 and 
30ms for the MS2 scans.
Data Processing and PeptideAtlas Assembly
The processing of collected MS data followed the general workflow of Farrah et al.32 with 
the Trans-Proteomic Pipeline18 as the main component (Figure 1).
First, vendor .RAW files were converted to the mzML format33 using the ProteoWizard34 
msConvert tool version 3.0.794. Next, the mzML files were searched using both Comet35 
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and X!Tandem36 with the hrk-score plugin. The chicken search database was compiled as a 
nonredundant union of 24,231 chicken sequences from UniProtKB/TrEMBL, 16,354 
sequences from Ensembl release 82,37 and the cRAP database. For Q Exactive files, parent 
mass errors were set to ± 20 ppm with product ion mass tolerances of ± 20 ppm for X!
Tandem and ± 0.03 Da for Comet. LTQ-FT data used a parent mass error of ± 50 ppm and 
product mass tolerance of ± 0.4 Da for both X!Tandem and Comet. Searching allowed semi-
tryptic peptides and a maximum of two missed cleavages. A static modification of 
carbamidomethyl on C, and a variable modification for oxidation on M, acetylation of 
protein N-termini, and pyro-glu on Q, E, and C were also used. For samples processed with 
deglycosylation, a variable modification of deamidation on N was also searched.
The search results were processed with the TPP 18,38 version 4.8.1 tools. The pepXML17 
output for Comet was used directly, and the TPP tool Tandem2XML was used to convert the 
native X!Tandem output to pepXML. For each experiment, the set of pepXML files from the 
two search outputs were processed together with PeptideProphet.39 The two output files 
were then combined via iProphet.40
The iProphet output was further processed using the reSpect algorithm20 to access spectral 
chimeras. During reSpect searching the precursor mass tolerance was increased to match the 
MS isolation window. For LTQ-FT data the parent mass tolerance was increased to 2.0 Da 
and likewise increased to 1.4 Da for Q Exactive data. The new set of mzML files generated 
by reSpect were searched and processed using the TPP as for the initial files. For Q Exactive 
data, this process was repeated an additional time, for two complete rounds of reSpect in 
total. The spectra used for reSpect were filtered for a minimum iProphet probability ≥ 0.0 
during the initial round, and ≥ 0.5 for the second round of analysis.
Using the PeptideAtlas processing pipeline, all the iProphet results from standard and 
reSpect searches were filtered at a variable probability threshold to maintain a constant FDR 
threshold for each experiment. The filtered data was assessed with the MAYU software41 to 
calculate decoy-based FDRs at the peptide-spectrum match (PSM), distinct peptide, and 
protein levels. All results were collated in the Chicken PeptideAtlas, available at http://
www.peptideatlas.org.
RESULTS & DISCUSSION
Overview of the PeptideAtlas
The chicken PeptideAtlas represents the most extensive collection of publicly accessible 
proteomic data for Gallus gallus, an important economic organism and resource tool. The 
database incorporates data from individual birds in various cancerous disease states, and 
fully samples the reproductive tissue, including differentiated portions of the ovary (i.e. 
small white follicles, ovarian stroma, etc.), which are nearly unexplored (Table 1).26 The 
extensive sampling is enhanced by high resolution MS and MS/MS IT-CID and HCD data 
collected from both LTQ-FT-ICR and Orbitrap instruments, providing the highest quality 
mass spectra in order to support further study of reproduction and cancer biology in hen 
based systems.
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Accessing the PeptideAtlas is accomplished through a readily accessible web GUI, 
providing observation information at both the protein and individual peptide level. Proteins 
and peptides of interest can be accessed using a sequence and/or list of accession number 
derived from Uniprot or Genbank This information can be readily used for comparisons 
between individual proteins contained in a single PeptideAtlas build, across species within 
the broader PeptideAtlas project, or generated from other sources such as KEGG or 
Reactome pathways.42,43
The chicken PeptideAtlas incorporates mass spectral data from over 800 individual 
biological experiments containing over 8 million spectra. The current build includes 5 
million PSMs with an FDR threshold of 0.01% and over one hundred thousand distinct 
peptides at a false-discovery rate of 1%. This translates into 6,646 canonical proteins at a 
protein FDR of 1.3%. A substantial number of additional proteins are at least partially 
distinguishable, meaning that they possess at least one unique, well detected peptide within 
the chicken PeptideAtlas; the total number of observed proteins is 11,370, corresponding to 
47% of Gallus gallus’ 23,997 predicted gene products based on the UniProtKB/TrEMBL 
database. A sizeable fraction of these detected species exist at the single peptide level, which 
is to be expected based on the reproductive system focus of the current datasets. Future 
inclusion of additional sample types is expected to increase the overall gene product 
coverage of the chicken PeptideAtlas.
Chimeric MS/MS reSpect Analysis
One of the basic assumptions of MS/MS data processing is that the fragment ion spectra 
obtained are derived from an individual precursor molecule isolated by MS. In spite of 
continued advancement in MS, precursor isolation windows remain relatively large to the 
achievable mass accuracy of the analyzers. Further, the complexity of whole proteomes 
remains well beyond the separation capacity of current chromatographic systems. The end 
result is that fragment spectra are frequently “chimera” containing peptide fragments from 
multiple precursors. While this is sometimes an intentional byproduct of the acquisition 
method, as in data-independent analyses, the collection of chimera can significantly reduce 
identifications in data-dependent sampling of complex samples due to the algorithmic 
MS/MS interpretation limitations44,45. This build of this initial chicken PeptideAtlas 
incorporates data processed with the newly developed reSpect tool,20 which enables multiple 
processing of complex MS/MS spectra to isolate co-fragmented chimeric peptides and 
increase overall peptide/protein IDs.
Examining the output of the reSpect reveals the effect of its inclusion on the chicken 
PeptideAtlas coverage. New peptide identifications derived from the reSpect output account 
for 825,135/5,125,800 = 16.1% of the total PSMs included in the chicken PeptideAtlas, only 
five specific instances of which corresponded to the identification that would originally have 
been assigned by a standard search. This frequency of spectral chimeras is in concordance 
with previously reported values.45 Within the chimeric group, 653,874 (79.2%) of the 
identifications have precursor masses falling outside the m/z tolerances of the initial search, 
and are therefore unintentional precursor inclusions as the result of wide precursor isolation 
windows. Interestingly, 378,194 (45.8%) of the PSMs were obtained from spectra that were 
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assigned a ≥ 90% probability in the initial search, while a roughly equivalent number, 
387,714 (47.0%), were from spectra whose assignment was given a probability of < 50%. 
Therefore, the chimera spectra seem to be equally likely to be minor components of an 
otherwise identifiable spectrum or major interferents who impinge spectral assignment.
Regardless of the source or intensity of the chimeras, the reSpect step was able to improve 
the depth of PSM and peptide identification by an appreciable margin. For the most part, the 
additional PSMs correspond with peptides that are already included as the primary ID from 
another spectrum. However, 8,976 unique peptides were identified only as the result of 
reSpect processing, corresponding to ~ 8% of the total peptide IDs in the chicken 
PeptideAtlas. The inclusion of additional unique peptide IDs is obviously of significant 
importance given the goal of complete organism coverage, but additional validation of 
already identified peptides is likewise important for increasing the confidence of spectral 
assignment when combining the results of multiple searches in iProphet.40
Ovarian Cancer Biomarkers in the Chicken PeptideAtlas
Ovarian cancer (OVC) is the most lethal of the gynecological cancers, with the single most 
important prognostic marker being clinical stage at diagnosis.46,47 Currently, the vast 
majority of OVC cases present in later stages47,48 and, as consequence, there is substantial 
interest in discovering biomarkers for early stages of the disease.49,50 To this end, the 
domestic fowl has rapidly emerged as a uniquely suited organism for the study of 
spontaneous ovarian cancer.51–54 Throughout the past 75 years, pathological examination of 
the hen has noted that spontaneous ovarian tumor formation occurs in up to 35% of the 
population and presents with the same histopathological subtypes seen in human disease.
55–58
 An extensive degree of molecular investigation has identified both human similar 
molecular expression and novel markers using mRNA expression analysis and 
immunohistochemistry (IHC) based assays.59–65 One major limitation of the model is the 
lack of commercially available chicken specific reagents for IHC and Western Blot analysis; 
the use of cross-reactive human antibodies has yielded inconsistent results, especially in the 
case of CA125, the primary prognostic marker for human OVC.66–68 The PeptideAtlas is a 
powerful resource for mining of proteotypic peptides to develop SRM-based methods69 that 
can augment or replace inconsistent mRNA and IHC approaches.70–72 Further, the current 
sample set is an empirical examination of the existence of many biomarkers previously 
unexplored by LC-MS/MS. Several examples of chicken biomarkers will be discussed. An 
extensive, but by no means complete, list of ovarian cancer associated proteins can be found 
in Table 2 and in a previous review by Hawkridge et al.53
Localization of Serine Protease Inhibitors
Serine protease inhibitors (Serpins) are a superfamily of protease inhibiting proteins 
ubiquitous to eukaryotic organisms whose regulatory members share a unique mechanism of 
irreversible “suicide inhibition” of target preoteases.73–75 Because protein homeostasis is 
controlled by proteinases and their inhibitors, this superfamily has attracted attention in the 
field of cancer biology, where tumor progression necessarily requires disruption of 
homeostasis.75,76 Within the family, specific proteins have been identified as prognostic 
biomarkers,77,78 tumor tissue markers,79 and potential diagnostic markers for a range of 
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cancers,80–83 examples of which will be discussed further. Searching the chicken 
PeptideAtlas for proteins that have a description that contains “SERPIN” yields 18 unique 
protein groups from multiple subgroups of the serpin family, including many of interest in 
cancer research.
Serpin class “A” molecules are one of the largest serpin groups in humans, consisting of 
extracellular molecules.75 Five chicken orthologs of this class (E1C7T1, F1NPN5, E1BS56, 
E1C206, and F1NPN4) were identified in the chicken PeptideAtlas with an average 
coverage of 70%. As expected, excreted species are observed in plasma and liver tissue. Two 
of the species however, are also observed in hen reproductive tissues. SERPINA1 (E1C7T1, 
alpha-1-antitrypsin) is the most common serum serpin and its misregulation has been 
associated with endometrial and cervical cancer in humans.84 SERPINA3 (F1NPN5, 
alpha-1-antichymotrypsin) has likewise been associated with the promotion of endometrial 
cancer cells, as well as numerous other cancer types.85 The detection of these potential 
biomarkers in endometrial tissue of the chicken ovary is not unexpected, but cancerous 
associations derived from human studies have not been confirmed in the chicken. This 
relationship is worthy of further MS studies in the chicken model system, with particular 
emphasis on the translation of disease behavior between species.
Serpin class “B” molecules are generally intracellular proteins and similarly to class A are 
frequently associated with regulation and disease;76 the current chicken PeptideAtlas build 
contains three such proteins. SERPINB11 (P01013) is an important regulator of estrogen 
expression in chicken oviductal tissue; it is implicated in both normal oviduct development 
in the chicken and the development of ovarian endometrial cancer.59,79 Peptides from this 
protein were identified with 100% sequence coverage across healthy and cancerous oviduct 
tissues, consistent with its specific role in that tissue type. Interestingly, while identifications 
in plasma or liver tissue are limited to single observations, SERPINB11 peptides can be 
identified at consistent low levels in ovary samples from some healthy individuals, as well as 
in cancerous samples. This is consistent with the low levels of expression seen in RT-PCR 
experiments with developing ovarian follicles79 but the potential for ovarian tumors to 
originate from oviduct or mullerian cell incursion is considered quite high.86 The monitoring 
of cellular migration in the hen reproductive system offers the potential for understanding 
the biological origin and progression of ovarian cancer, which will aid in our understanding, 
detection, and treatment of the disease.
Additional serpins common in specific sample types are associated with multiple disease 
states and biological stress responses. SERPINC1 (F1NLP7, Antithrombin-III) and 
SERPINH1 (P13731, Hsp47) are among the most abundant proteins detected in plasma 
samples within the PeptideAtlas, as befitting their roles in blood. Antithrombin-III is an 
anticoagulant shown to be effective prognostic markers for some cancer types due to the 
systemic response to carcinogenesis,87 but more commonly used as a protein therapeutic.88 
Hsp47 meanwhile, is of interest due to its relationship with thermal regulation and stress.89 
It is therefore apparent that in addition to its use as an ovarian cancer model system, the 
included samples allow for the creation of experiments addressing additional diseases and 
biology of interest in chickens.
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Acute Phase Proteins in the Chicken PeptideAtlas
One of the broadest diagnostic tools for the investigation of systemic response to stressors is 
the acute phase response (APR). The APR is a generalized systematic response of the 
immune system to numerous events, including trauma, inflammation, infection, stress, or 
carcinogenesis, with the goal of restoring organism homeostasis and promoting healing.90 
Acute Phase Proteins (APPs) are hepatic proteins produced as the result of pro-inflammatory 
cytokines during trauma and are a powerful tool for examining immune and stress response.
91
 The initial description of APPs involved the changing concentrations of plasma C-reactive 
protein in response to pneumococcal infection92 but has since expanded to encompass 
numerous plasma proteins in both human and non-human animal systems.93,94 Generally, 
the APPs are divided into classes based on whether they increase or decrease in 
concentration in response to the APR, as well as the magnitude of the change. This 
expression can be highly species specific, requiring the development of unique assays and 
the selection of unique assay targets for different study organisms.93
APP profiles in many species have been used as diagnostic tools and as a mechanism to 
understand the biological response to system challenge, such as infection.95 Unsurprisingly, 
various APPs in the chicken (Table 2) have likewise been thoroughly classified by response 
and magnitude.96 Albumin is the only notable negative APP (relative abundance decreasing 
upon immune challenge) in the chicken, but with plasma concentrations approaching 20 
mg/mL it is a trivial target for proteomic analysis.97 The positive APPs range in 
concentration from ng/mL – μg /mL quantities and their responses can be categorized as 
major (≥10-fold abundance increase), moderate (4–10 fold), and minor (≤3 fold).96–98 
Monitoring APPs at these levels has previously relied on enzyme-linked immunoassays 
(ELISA), often using partially cross-reactive murine or human anitbodies.99 This method is 
undesirable for the discovery of avian APPs, due to cost, laboriousness, and frequent lack of 
similarity with more well understood mammalian systems. For example, haptoglobin is an 
very common APP in a wide range of species,91 but it was not until the chicken genome was 
sequenced that it was determined that no homologous protein exists in G. gallus;100 an 
antioxidant protein from gene PIT54 fills the hemoglobin binding role in chickens instead.
100,101
 Invaluable information on novel APP proteins, as well as thorough investigation of 
existing APPs will be greatly enhanced by the application of quantitative mass spectrometry 
techniques enabled, in part, by quality peptide and spectral libraries.
The chicken PeptideAtlas contains extensive liver and plasma samples from both healthy 
and diseased chickens, and contains all well-studied APPs in the organism (Table 3). Due to 
the underannoted nature of the chicken proteome, many APPs contain multiple potential 
variants in the global UniProtKB/TrEMBL database that are grouped by the chicken 
PeptideAtlas under the most likely canonical form. The PeptideAtlas can be used to explore 
the existence of one or more protein isoforms, as well as a starting point for the development 
of distinguishing assays.
Hemopexin Polymorphism
Hemopexin is an acute phase serum glycoprotein with enormous binding affinity for free 
heme, and is found across multiple animal families.102 The protein was initially isolated on 
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the basis of its heme-affinity103 and has multifunctional properties in iron-metabolism.104 
However, it has been shown to be APP based on regulated expression in response to 
hormonal stimuli,105 and infection with various pathogens,106–108 which is believed to be its 
primary biological role.104
The chicken PeptideAtlas contains multiple entries for chicken Hemopexin proteins derived 
from multiple sources. The manually annotated UniProtKB/Swiss-Prot database contains 
chicken protein P20057, which is an N-terminal fragment rather than a complete protein,109 
while the UniProtKB/TrEMBL database contains an entry from the chicken genome 
(ENSGALG00000022586 / H9L385) as well as a non-genomic sequence fragment from a 
partial cDNA library (Q90WR3). Mutual alignment of the sequences revealed virtually no 
similarity between the manually determined N-terminal sequence and either of the other 
forms, while H9L385 and Q90WR3 possess 99% sequence similarity within the fragment 
region (Figure S-1 and S-2). The observed peptides within the chicken PeptideAtlas yield 
over 98% sequence coverage for the genetically derived data, while no portion of the 
manually determined sequence could be identified, casting doubt on its veracity. Within the 
two genetic sequences, three polymorphisms can be observed, two of which (p.Arg282Met 
and p.Lys148Arg) are not addressable because the small peptides constitute the unobserved 
2% of the sequence. However, variants of the remaining polymorphism (p.Arg235His) were 
detected with unique peptides. The peptides CSGEPFQAITSDDSGR from H9L385 and 
CSGEPFQAITSDDSGHIYAFR from Q90WR3 (polymorphic site noted) were each 
observed in several hundred quality spectra across experiments, many with nearly full y-ion 
series, lending credence to the existence of the non-genomic protein sequence. 
Disaggregation of the samples to examine individual organisms from a published study24 
reveals that specific chickens can present with either one or both of the sequences. Chickens 
#602, 612, 630, 639, and 666 exhibit peptides from both sequences, while #600, 601, and 
650 exhibit only the unique peptide from H9L385 and #620 exhibits the form from 
Q90WR3, implying both hetero- and homozygosity of the polymorphism occur in the 
population. The chicken PeptideAtlas thus reveals the existence of multiple forms of a 
common chicken APP and provides peptides suitable for quantification of either individual 
polymorphisms or total protein.
Peptide Deglycosylation
N-linked glycosylation is an extremely common post-translational modification consisting 
of potentially diverse oligosaccharide structures linked to asparagine residues at a conserved 
sequence motif (N-X-(S/T), X≠P) and which affects the majority of gene products.110 The 
modification that occurs is a non-template driven process and due to the availability of N-
glycan precursor, the accessibility of the glycosylation site, and the variable transit time of 
proteins, the majority of glycosylation motifs are not modified by sugars; others exhibit 
partial or complete occupancy, which can have significant implications for their biological 
function.111,112
During sample processing for the chicken PeptideAtlas a representative number of samples 
were deglycosylated using the enzyme peptide-N-glycosidase F (PNGase F) to cleave N-
glycans and generate a detectable asparagine deamidation (mass shift: +0.9848 Da). This 
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processing has a two-fold implication on the resulting peptides: increased peptide coverage 
from detection of newly deglycosylated peptides, and identification of potential 
glycosylation sites for future study based on the co-occurrence of the glycosylation motif 
and asparagine deamidation. The latter is usually performed with 18O water to provide 
unambiguous identification of enzymatic deamidation,113 but this is unfeasible for a project 
of this size. Nevertheless, a processing method designed to reduce non-specific deamidation 
combined with high resolution mass spectrometry enables accurate site determination 
sufficient for initiating deeper study.28,114
The protein prothrombin is an important coagulation precursor with multiple known 
glycosylation sites in different species.115 The glycosylation of these sites is important to 
protein function and processing, but different species exhibit different numbers of active 
glycosylation sites.116,117 The protein sequence in the chicken (UniProt Accession: 
F1NXV6) is 607 amino acids long and contains four potential N-glycosylation motifs at 
Asn122, Asn144, Asn161, and Asn403 which are homologous with the four sites observed 
in the human form of the protein (Figure S-3). Specific deamidated versions of each of the 
four potential glycopeptides (GTInYTK, FnASIYPDLTENYCR, NPDnNSEGPWcYTR, 
and nLTTNDILVR) were able to be observed, as well as longer fragments containing miss 
cleavages. Of the tryptic peptides, three of the four were observed only in deglycoslated 
samples, and were observed only in their deamidated forms; this implies that these sites are 
wholly glycosylated and the identification of these peptides is entirely related to the PNGase 
F processing. In contrast, one of the peptides (NPDNNSEGPWCYTR) was observed in both 
deamidated and non-deamidated forms in the deglycosylated samples, as well as being 
identified in the PNGase F free preparations, implying only partial site occupancy. Direct 
comparison of biological samples 6755 and 6798 (Table 1) showed a 70% increase in the 
number of peptide observations as the result of the inclusion of deamidated, and therefore 
deglycosylated, peptides. Homology comparison to humans would predict that the three 
wholly glycosylated sites would be the only occupied sites.115 However, the rigorous 
identification of a partially occupied site could point to a different structural or processing 
role in the chicken than the human, which could be worthy of further study.
CONCLUSION
The initial build of the chicken PeptideAtlas represents over 100,000 high confidence 
peptide identifications from MS/MS spectra corresponding to nearly 50% of the translated 
chicken proteome. The collection is rich in representative proteins of substantial interest in 
future health research in both chicken and human. Herein we have demonstrated the 
coverage of the chicken PeptideAtlas for an expansive number of proteins relevant to the 
chicken as a model for human ovarian cancer, important for investigations of systemic 
inflammatory responses in a veterinary context, and of general biological and agricultural 
interest to the study of the chicken organism. The chicken PeptideAtlas provides a readily 
accessible repository of information on the MS observable chicken proteome, providing a 
basis for proteomic experiments in the assay of known proteins, useful for discovery of 
novel biomarkers, and validation of genomic information at the proteomic level. We have 
demonstrated the use of this information for the isolation of single amino acid 
polymorphisms in inflammatory proteins as well as localization of tissue specific markers at 
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the sample level within the chicken PeptideAtlas. This powerful resource is freely available 
to mine data for efforts such as in biologically driven hypotheses of both human health and 
agricultural interest and for approaches in biomarker discovery for quantitative MS assays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic workflow of the PeptideAtlas build process.
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